1193
473) 897
nulclear 978
year 558
numerous 640
nestin 27
[24] 1031
texas 361
without 688
would 1139
outcomes 554
[25] 1056
poor 237
recruiting 403
understanding 168
cyclophosphamide 758
doxorubicin 627
near 663
phosphorylation 932
topotecan 785
successfully 1018
solid 399
vincristine 585
frames 894
excellent 773
rapalogs 1115
notably 862
( 665
) 668
* 24
p13k 1037
+ 942
[23] 1030
analysis 153
80% 243
version 449
apparent 848
0 54
marrow 737
1 2
2 55
3 418
4 598
exposure 1123
left 566
5 916
ewing 6
6 965
7 798
inactivation 1099
8 823
: 482
appropriate 307
providing 1067
weeks 463
role 1130
(?clia?) 550
subsequently 352
(right 905
result 607
?50% 908
microanatomical 875
[27] 1142
targeted 3
inhibitor: 15
irb 470
control) 913
certified 545
after 138
rational 299
patients) 404
hand 893
follows: 395
g 1102
loops 266
i 332
onset 441
blood 231
uroprotection 600
q 745
consisting 747
component 867
trials 205
[26] 1064
pathway 23
days 763
persistence 927
combined 100
plasma 1079
novel 1184
thr 34
rapamycin 105
surgery 184
standard 744
nine 714
hybridrization 606
controls 539
evidence 736
p04720am3) 415
(plasmalemmal) 31
(igf1r)-targeted 311
assessment 162
post 887
igfbp3 1051
protocols 466
473)and 485
faint 925
(specimen 886
constitutively 956
often 1038
consent 369
fusion 1046
i/ii 1001
therefore 324
activation 150
permitting 918
useful 1189
p-erk 32
neural 857
applied 114
young 177
(1800 762
(phase 406
previously 480
scope 389
end 783
lines 1155
responded 353
pilot 93
identify 305
approval 471
chromogranin 576
erlotinib 635
blocks 1028
multiple 396
perform 552
pulmonary 641
improvement 547
p-akt 38
better 86
noted 670
ranging 871
(clinicaltrials.gov 1006
there 843
clone 608
well 152
platelet 695
progressive 804
detected 864
cancer 278
gtp-bound 1106
ras/raf/erk 1150
family 842
ewing's 83
osteosarcoma 413
rearrangement 611
referred 636
refractory 241
biotechnology 501
(igf1r) 75
focus 672
occurs 1134
approach 182
[cell 490
signatures 169
number 80
responding 1174
mg/m2/course 752
precursor 958
per 221
pet 818
synaptophysin 969
similar 841
modulate 1111
testing 309
understand 87
putative 933
underlying 263
resonance 570
recurrence 833
ever 212
even 330
drives 1022
cancers 422
larger 1165
other 1143
woman 561
against 661
p13k/akt/mtorc1 846
pip3 1084
factor-1 12
cell 233
local 779
pip2 1083
radiographic 127
indicating 939
top 977
acquiring 1177
transplant 234
elucidate 354
outcome 202
erk 151
particularly 298
linear 1040
robust 1168
dominant 948
drugs 291
identifiers 394
desmin 578
ascending 397
produce 294
patient's 678
removed 813
phosphatidylinositol 1072
(tyr 120
regard 517
(pet/ct) 455
markers 967
inhibitors 283
measuring 644
biological/clinical 327
minor 866
almost 844
findings 270
akt 945
www.clinicaltrials.gov 388
trial 392
points 831
downregulated 1148
optimize 210
all 386
new 442
downregulates 1049
including 1144
below 556
20% 246
less 245
carpinteria 507
(from 907
clinical 201
intervals 430
204 36
improve 200
(not 970
ews-fli1 1045
(now 400
lesion 733
susceptibility 281
initiated 629
university 360
(endothelial 910
progression 632
upregulates 1052
auto-activity 1112
effective 980
(doxil) 628
ras/raf 18
igf1r-based 986
similarly 994
p-mtorp-aktp-stat3 889
upregulated 1012
possibility 1129
mg/m2/day 592
(2500 596
tsc1/2 1097
rates 336
sacral 573
specific 284
nj) 655
followed 99
despite 179
any 689
stable 812
extending 725
long-term 1024
unidentified 1182
oncology 740
leg 721
473 40
thorax 704
generalized 950
lesser 952
nct00880282 1008
protein 1047
upregulation 136
igf1 1075
(r1507) 705
dose) 768
fully 656
panel: 711
semi-quantified 516
using 180
magnifications 914
adolescents 176
began 801
investigating 1002
expected 1140
multimodal 181
completed 784
recognize 321
three-year 563
relapsed 137
reacted 540
(schering 790
molecule 1069
abrogates 1025
25% 961
increased 1156
frequently 250
panels 440
another 301
indicative 923
3-kinases 1073
(pi3k) 1074
two 96
p-extracellular 486
nct00400361 405
ifosfamide 595
found 675
endothelial 855
taken 433
reported 340
event-free 244
(as 370
igfr 1131
mechanism 1014
genetic 1186
occurred 343
pi3k 1082
morphoproteomics 275
plasmalemmal 532
inhibit 1118
combining 183
summarized 555
non-staining 523
(temsirolimus) 713
such 1157
similarities 826
pre-igf1r 885
[iv]on 588
tumor 124
igg1 658
dataset 1166
p-erk1/2 118
fashion 1098
resulted 77
through 203
4-week 429
toxicity 669
medical 357
lessening 1065
predominantly 936
lesions 642
caucasian 560
remains 236
run 537
(nct00006734) 743
occasional 900
(rictor 941
tyr 45
+/�?? 51
retrospectively 1162
adjuvant 614
cytoplasmic 533
cambridge 510
starts 1109
recurrent 123
results 160
acquired 990
given 258
chest 699
last 988
involves 277
might 139
significant 1191
expressions 505
imaging 571
decrease 694
mechanistically-diverse 214
termsirolimus 1019
improving 796
signals 513
institutional 381
cohort) 423
leads 1094
overall 192
next 1170
absence 903
show 700
resistant 147
metastases 619
not 338
negative 538
central 583
stat3 26
now 1104
and/or 534
factor 74
derived 385
early 207
down-modulates 1138
pain 565
hours 757
disease 238
appropriately 541
center 364
expression) 963
yet 339
bone 174
target 104
bypass 992
alternating 761
adriamycin 590
igfr/mtor 1136
signal) 66
initially 365
short 1119
risk 240
time 830
precursor/differentiation 858
aews0031 742
post-anti- 870
criteria 447
(1�??3+) 50
program 359
(mri) 572
three 648
ir/igf1r 1066
prospectively 1164
her 624
options 247
suppression 1133
[santa 499
greater 917
upregulate 1141
images 891
gene 610
conclusions 1169
(ser 483
immunopositive 856
705) 121
determined 445
etoposide 622
primary 143
care 211
1988 549
study 94
tolerated 687
methods 542
differences 827
merits 164
formation 1023
confirmed 602
unknown 347
?igf1r+ 922
tomography 454
bilateral 734
plateau 188
probes 113
inhibits 1114
preponderance 898
chain 1095
initial 125
more 213
(igf-1r) 14
fdg 817
unfortunately 989
consistent 845
bedside 272
reverse 1175
performed 85
compartments 840
heterogeneity 259
(0�??3+) 57
brightfield 514
chemotherapies 215
cruz 500
board 383
twenty-four 557
small 79
reveal: 895
membrane 1080
before 832
cycles 581
used 474
experience 350
malignant 173
mammalian 103
protocol 809
outlined 371
shows 707
his 771
shown 312
p-signal 494
major 690
infusion 754
(mtor 1091
presented 562
percentage 518
day 589
potential 1003
combination 133
described 667
group 741
pathological 575
signal-regulated 20
survival 193
history 432
done 807
(high 68
both 132
most 171
ser473 946
effects 692
marker 859
counteract 1057
explaining 145
p-mtor) 943
who 156
ser2448[nuclear] 42
largest 643
part 465
their 261
[10] 314
(ihc) 473
igfr-mtor 1132
alone 98
intravenous 582
along 436
patient 28
specimen 837
(biopsy 882
(500 770
(p) 477
san 683
rictor) 1093
original 122
correlative 944
therapy 92
[1] 194
morphoproteomic 4
clear 341
a) 881
(no 65
approaches 242
increase 906
>50% 59
?igf1r 888
depicting 878
various 262
investigation 166
microscopy 515
latter 929
further 165
visit 431
clinic 637
succumb 981
account 1151
temozolomide 788
been 189
pre-treatment 708
twenty-one 718
[2] 195
b) 883
reflected 838
[12] 316
evaluation 446
complex 940
?rapalog? 1062
sch 410
evaluated 426
generaration 1171
addition 300
staining) 529
grow 802
[3] 196
c) 920
[11] 315
symptoms 443
epitopes 323
dose 226
(0: 522
propensity 1153
profiling 5
(1+) 49
<10% 53
relative 1146
treatment 107
strong 528
stained 519
[4] 197
d) 921
myeloablative 229
monoclonal 660
cm�5.1 646
(18 794
how 268
[15] 329
proteins 1036
underway 1178
whom 158
assembly 1029
subsequent 141
nct01016015) 1009
term 1120
panel 706
sacroiliac 726
tomography/computed 453
enrolled 738
metabolic 438
ser 39
scoring 61
[5] 198
emergence 821
subjects 412
aberrations 1187
[13] 317
cm 647
overcoming 1190
right 710
(study 414
ct 457
55.8 774
[14] 328
subcellular 530
maximum 749
decipher 1181
705 46
under 546
(imca12+ 716
identifiers: 1007
transducer 495
[6] 274
promise 313
residual 674
developed 111
later 297
[17] 543
single-agent 110
surgical 676
antibodies 320
signal 955
prospective 308
possibly 286
[7] 288
needs 1160
(roche 653
remained 811
pathways 264
brown 976
imclone 682
717454 411
she 579
down-modulate 1032
downregulate 1063
month 985
202/tyr204) 489
[16] 481
(morphology+proteomics) 276
however 235
r1507 398
5.9 645
some 289
[8] 303
(up 901
response/resistance 88
beginning 206
biopsy(biopsy 880
nodules 735
additional 1068
intensity) 69
chromogenic 512
back 564
p-mtor 41
p-stat3 43
primarily 896
santa 502
(erk) 22
duration 219
[19] 793
analytes 849
perhaps 144
(cci-779) 421
2006 652
plos 372
related 1016
preclinical 991
(0?100%) 520
diego 684
(100 769
nuclear 535
(imca12)+ 712
human 657
[9] 310
recruited 1078
i) 407
over 755
/ct 819
digital 890
six 461
irinotecan 615
translocation 730
mg.) 750
compartmentalizations 531
50% 962
trajectory 293
tsc2's 1100
[18] 685
gy 775
kinase/extracellular 19
although 786
approximately 873
regression 296
high-complexity 553
comprehensive 437
showing 709
he 732
subset 335
explain 140
qualified 551
very 865
synergy 1004
transcription 497
advanced 81
(2 586
trisphosphate 1087
nodule 800
chemotherapy 185
fluorescent 604
improved 772
appeared 949
ma) 511
overexpression 1147
four 810
revealed 154
(37.5 591
context 1010
differentiating 287
guidelines 380
majority 924
whereas 860
ews-fli1-mediated 1058
1's 1013
705)expression 928
ii 337
(abcam 509
s6k-mediated 1113
likely 938
underwent 580
large 723
beverly 492
lower 567
index 351
being 603
iv 593
operative 1070
resulting 1054
nutley 654
radiating 720
lung 618
(9000 765
kinase 21
3.1 450
contrast 847
interval 224
status 391
acting 1033
machinery 1061
** 44
thoracoscopic 806
ma] 493
anti-igf1r 680
eventually 787
emerged 148
t(1122) 729
cycle 222
targets 1096
eight 462
products 1081
torc2 1017
nct00617890 416
torc1 1020
december 651
graded 63
man 719
table 1
predicting 280
1+: 524
side 691
(ser2448) 116
may 325
within 662
max 766
could 1015
rheb 1103
change 191
biologic 1135
specimens 17
positive 71
off 803
agents 252
+: 526
antibody+ 715
exome 1172
(phosphatidylinositol 1085
report 349
complete 664
(19d12) 792
(irb) 384
post-igf1r+ 972
several 1000
solitary 799
serve 911
x400 915
short-term 1021
while 146
second 170
suggests 161
high 983
mutations 1185
md 362
publication 374
continuous 753
reviewed 356
lungs 679
kenilworth 791
mg 587
expressed 869
directly 273
different 322
chronic 1122
combine 251
nuclei. 73
progressed 625
peripheral 230
months 616
level 1076
occur 998
diagnosis 239
schematic 877
plus 102
relevant 1188
present 48
recist 805
since 1137
no 29
differentiation 966
predominant 851
counterproductive 996
total 767
1/2 487
hour 760
physical 434
included 217
determine 408
anderson 363
sought 209
control 780
depicted 1039
decreasing 223
suppresses 1124
temsirolimus) 717
(600x) 975
enrollment 789
mtorc 1121
intensity 62
tumors 260
receptor 13
345 1086
radiation 186
manuscript 366
due 1149
pretreatment 16
chemotherapeutic 285
keratin 577
biopsy 728
mtor 131
activated 155
202/tyr 35
(ser473) 117
counts 696
ewsr1 609
about 459
registered 387
(mtor) 106
unresectable 781
sequencing 1173
emission 452
exert 326
1) 256
above 472
concurrently 536
magnetic 569
1+ 52
moderate 527
extremity 568
proton 816
based 984
14 697
15 677
16 825
old 559
liposomal 626
19 795
herein 348
signatures. 1192
received 612
then 129
benefit 253
pdk1 1077
secondary 346
investigational 376
form) 373
2) 267
mlst8+raptor) 1105
2+ 58
consistently 982
except 693
obtained 458
20 671
dosage 220
functional 355
discovered 620
(1200 759
activity 409
insulin 1034
outset 255
scan 638
(left 892
seen 142
current 390
3+ 67
actively 402
3- 428
so 331
31 776
positron 451
rapamycin-induced 997
(stat)3 498
34 1088
**percentage 70
stopped 631
middle 822
expression 839
strategies 216
accordance 379
one 135
hematologic 439
analyzed 1161
started 621
adhesion 1158
immunohistochemical 112
detectable 926
extensive 919
compression) 227
showed 149
increasing 218
closed 401
progress 808
small-molecule 282
2448) 484
attained 190
vast 957
but 630
circumvent 995
ser2448 935
high-dose 228
joint 727
separate 469
48 756
available 319
presentation 731
loop 1110
details 375
written 367
up 872
50 987
phosphorylates 1107
five 623
igf1r 90
substrate 1035
treated 9
(thr202/tyr204) 119
children's 739
doxorubicin(75 751
degree 953
s6k 1026
collection 378
phosphorylated 476
antigens 478
finding 1011
sections 464
insulin-like 10
remarkable 126
enhanced 1055
/igf1r 1060
imca12+temsirolimus 820
once 108
laboratory 544
(0?1+) 960
region 876
higher 973
allow 1167
assessed 95
(nct00678769) 686
imc-a12 419
records 358
figures 964
sequential 649
adults 178
mass 574
igf1r-antibody 128
detect 115
[nuclear] 37
non-responding 814
we 84
immunonegative 861
regions) 909
initiation 425
common 172
interest 1152
examination 435
gap 1101
/erk 930
tumorigenesis 1125
every 460
mesna 599
figure 666
cases 290
post-treatment 904
metastatic 82
(irs1) 1071
dramatic 342
inhibition 157
(i.e 225
technology 491
(ir) 1059
cd56 968
resection 601
renewed 295
cells 279
constitutive 835
removal 634
nct00678769 424
fractions 777
igf1r-resistant 850
stem 232
ii) 417
binding 1050
whole 782
during 834
type 659
therapeutic 187
feedback 265
shown) 971
variably 868
children 175
scans 456
review 382
resistance/response 1159
mlst8+ 1092
presence 947
days) 594
guide 167
between 828
attempts 199
phase 249
antibody 97
response) 702
magnification 974
(temsirolimus 1116
ihc 504
inhibitor-based 91
collaborative 204
(imc-a12 681
baseline 1126
resistance 109
push 748
fail 292
toward 1154
combinations 306
re-emergence 824
among 1043
following 475
registration 393
activator 496
nuclei 829
internal 912
(thr 488
pelvis 778
distribution 937
our 159
evidenced 931
out 468
weak 525
uniform 951
continues 703
malignancies 1005
case) 1117
igf-1 1053
demonstrated 334
event 1090
1970s 208
informed 368
situ 605
(cytoplasmic) 47
mri 722
continued 650
suggest 1128
cd99 30
help 1180
site 934
bisphosphate) 1089
tumoral 72
temsirolimus 420
).the 1145
elements 1044
unravel 1183
responses 78
10.1371/journal.pone.0018424.t001 0
first 879
pet/ct 698
sarcoma 7
data 377
staining 521
biopsies 854
amendments 548
ca) 508
clearly 1041
minority 345
translate 269
[20] 852
drug 302
follow-up 617
growing 673
inhibitor 101
deciding 257
enlargement 639
(complete 701
p-stat3(tyr705) 863
only 344
(primary) 954
mechanisms 89
hallmark 1048
therapies 76
bench 271
like 1108
disappeared) 797
bottom 979
patients 8
published 479
one-half 874
?20%) 902
iliac 724
biopsied 815
pre-anti-igf1r 836
clinically 427
pkd1 1027
ca] 503
potentially 304
(dakocytomation 506
signaling 163
week 746
challenges 254
line 584
1?5 764
weakly 959
[22] 999
scale 64
targeting 993
validated 1163
mg/m2 597
array 1176
observations 1127
studies 333
thoracotomy 633
immunohistochemistry 884
regimen 134
carried 467
postoperative 613
limited 248
will 1179
[21] 853
interplay 1042
mtorc2 25
mtorc1 899
currently 318
(recist) 448
response 130
compliance 444
growth 11
(2+) 56
� 33
*maximum 60
